Shilpa Medicare Share Price

Shilpa Medicare

CMP as on 25-May-22 15:59

₹ 431.65
-21.30 -4.7%

Open

₹ 440.65

Turnover (lac)

₹ 1,797

Prev. Close

₹ 452.95

Day's Vol (shares)

₹ 4,16,305

Day's Range (₹)

₹ 426.00
₹ 440.70

CMP as on25-May-22 15:45

₹ 431.20
-22.05 -4.86%

Open

₹ 434.00

Turnover (lac)

₹ 71

Prev. Close

₹ 453.25

Day's Vol (shares)

₹ 25,208

Day's Range

₹ 426.20
₹ 444.80

Shilpa Medicare Ltd., formerly known as Shilpa Antibiotics was incorporated as a private limited company in November 20th, 1987 and has been promoted by Vishnukant C Bhutada and his associates. Shilpa Medicare Limited (SML) is engaged in manufacturing of Active Pharmaceutical Ingredients (API), Formulation and Development service. The company started its operations as API manufacturer way back in 1987 at Raichur, Karnataka- India. The company started commercial production in November 1989. In November 1993, Shilpa Medicare Limited was converted into a Public Limited Company. SML deals in high-quality Active Pharmaceutical Ingredients (APIs), Bulk drug, Intermediates, Formulations and Development service, New Drug Delivery Systems, Peptides / Biotech products and Specialty Chemicals etc. using sophisticated technology meticulously in order to comply with laid down international standards/specifications. SML is among the worlds leading suppliers of Oncology/Non-Oncology APIs and intermediates.Circa 1992, the company installed production facilities to manufacture sodium methoxide. During FY 2015, projects of five products transfer executed successfully, other projects of eight products have been completed and ready for transfer to plant. Ten new molecules have been taken for development considering future demand.During FY15, as part of mobilization of resources for the purpose of expanding the operations of the Company, fresh funds were raised by allotting 17,64,705 equity shares of Rs.2/- each to Tano Mauritius India FVCI II, the existing member of the Company, at a premium of Rs 423/-each on 15 May 2014 on preferential basis.During FY2016, the company after obtaining the approval of members at the 28th Annual General Meeting held on 28 September, 2015, divided the face value of existing equity share of Rs.2/- into two equity shares of Re.1/- each fully paid-up, with effect from the Record Date specified. Raichem Medicare Pvt Ltd., a subsidiary of Shilpa Medicare, completed installation of all machineries during the FY 2015-2016 and recruited all the key personnel, also commenced trial production in August 2015 after the Audit by External Consultant from Italy and started commercial production in December-2015. The subsidiary obtained the Drug Manufacturing license and GMP certificate and consent from pollution control board for operating the plant. In FY 16-17, Shilpa Medicare successfully launched the generic versions of Vidaza Injection & Xeloda Tablets. During the year under review, as part of mobilization of resources for the purpose of expanding the operations of the company, fresh funds were raised by allotting 30,25,000 equity shares of Re.1/- each to TA FII Investors Limited, at a premium of Rs.569/- each on 26 December, 2016 on preferential basis.Pursuant to the order dated 24 November 2017 of Honble National Company Law Tribunal, Bangalore Bench, the Navya Biologicals Private Limited has been merged with the Company with effect from 1 April 2016 being the appointed date for merger.In FY18, Shilpa Medicare entered into Share Purchase agreement with joint partner ICE SPA Italy to dispose off its entire stake in Raichem Medicare Private Limited. According to the terms of agreements, Shilpa Medicare has so far disposed off 24% stake in the company for which the consideration has already been received. The company is in the process of disposing the remaining 26% with prior approval of Reserve Bank of India.During the year 2019, an amount of Rs 22.71 crore was invested into its wholly owned subsidiary, Shilpa Therapeutics Pvt Ltd. (STPL) by way Loan and the amount was majorly to meet the project cost which is being set-up at Cherlapally, Hyderabad, Telangana, India.During the F.Y. 2018-19, the company invested in commercial papers of IL&FS Limited to an extent of Rs 1,437.28 Lakhs, due to be redeemed on 2 January, 2019. However, owing to recent financial crisis of IL&FS Limited, the board has completely provided for the loss.During the year 2019, the Company decided to make disinvestment in Raichem Medicare Private Limited, erstwhile Joint venture, and in furtherance of this, 4,17,962 equating to 24% of the equity share capital and 1,85,00,000 preference shares of Rs 10/- each, were sold to Joint Venture Partner ICE S.p.A.In FY 2019, the company incorporated Shilpa Pharma Inc. as a wholly owned subsidiary in United States of America.During the current FY 2019-20, the Company formed Sravathi Advance Process Technologies Private Limited to foray into the R&D activities of specific drug processes by roping prominent technocrats.

  • Chairman (Non-Executive)

    Omprakash Inani
  • Managing Director

    Vishnukant Bhutada
  • Non-Exec. & Independent Dir.

    Pramod Kasat
  • Non-Exec. & Independent Dir.

    Rajender Sunki Reddy
  • Non-Exec. & Independent Dir.

    Sirisha Chintapalli
  • Non-Exec. & Independent Dir.

    Piyush Goenka
  • Whole-time Director

    Sharath Reddy Kalakota
  • Addtnl Independent Director

    Arvind Vasudeva
  • Addtnl Independent Director

    Hetal Gandhi
  • Company Secretary

    Ritu Tiwary

Registered Office

#12-6-214/A1,
Hyderabad Road,Raichur,
Karnataka-584135

REGISTRAR OFFICE

Karvy Selenium Tow-B,
Nanakramguda,Hyderabad-500032
INDIA